Robert L. Ruxer

1.1k total citations
13 papers, 352 citations indexed

About

Robert L. Ruxer is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robert L. Ruxer has authored 13 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert L. Ruxer's work include Colorectal Cancer Treatments and Studies (4 papers), Cancer therapeutics and mechanisms (3 papers) and Cancer Treatment and Pharmacology (3 papers). Robert L. Ruxer is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Cancer therapeutics and mechanisms (3 papers) and Cancer Treatment and Pharmacology (3 papers). Robert L. Ruxer collaborates with scholars based in United States, France and Belgium. Robert L. Ruxer's co-authors include Alexander I. Spira, Marcus A. Neubauer, Marileila Varella‐Garcia, Fred R. Hirsch, Robert M. Jotte, Samir E. Witta, Paul A. Bunn, Karen H. Antman, Gordon F. Vawter and Joseph Aisner and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Robert L. Ruxer

13 papers receiving 344 citations

Peers

Countries citing papers authored by Robert L. Ruxer

Since Specialization

Citations

This map shows the geographic impact of Robert L. Ruxer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Ruxer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Ruxer more than expected).

Fields of papers citing papers by Robert L. Ruxer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. Ruxer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Ruxer. The network helps show where Robert L. Ruxer may publish in the future.

Co-authorship network of co-authors of Robert L. Ruxer

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Ruxer. A scholar is included among the top collaborators of Robert L. Ruxer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. Ruxer. Robert L. Ruxer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma 2016 ·Clinical Colorectal Cancer ·Daniel W. Bowles, Mark D. Kochenderfer, Allen Lee Cohn, Lucas Sidéris, Nghia Nguyen, (unknown), Ian D. Schnadig, Minsig Choi, Lisle M. Nabell, Arvind Chaudhry, Robert L. Ruxer, (unknown), Diana F. Hausman, Luke Walker, Alexander I. Spira, Antonio Jimeno	37
2	CD30 expression in nonlymphomatous malignancies. 2012 ·Journal of Clinical Oncology ·Jeff P. Sharman, Jerome H. Goldschmidt, John M. Burke, Beth A. Hellerstedt, Kristi McIntyre, Christopher A. Yasenchak, Thomas E. Boyd, Robert L. Ruxer, Dipti Patel‐Donnelly, Fadi S. Braiteh, Andres Forero‐Torres, Michael A. Savin, Tina Albertson	10
3	Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy 2012 ·Journal of Clinical Oncology ·Samir E. Witta, Robert M. Jotte, (unknown), Marcus A. Neubauer, Alexander I. Spira, Robert L. Ruxer, Marileila Varella‐Garcia, Paul A. Bunn, Fred R. Hirsch	156
4	Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial 2008 ·Journal of Thoracic Oncology ·Mark A. Socinski, Robert N. Raju, Marcus A. Neubauer, David A. Smith, Donald Richards, Michael A. Savin, Robert L. Ruxer, Craig H. Reynolds, Zhan Feng, Jane Bromund, Ruqin Chen, Coleman K. Obasaju	20
5	Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium 2008 ·Investigational New Drugs ·Thomas E. Hutson, Svetislava J. Vukelja, Daniel Atienza, Sanjay Awasthi, (unknown), (unknown), (unknown), (unknown), (unknown), Joseph J. Muscato, Robert N. Raju, Robert L. Ruxer, (unknown), D. Ilegbodu, (unknown), Steven J. Nicol, William R. Berry	4
6	Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer 2008 ·Clinical Colorectal Cancer ·Thomas H. Cartwright, (unknown), Allen Lee Cohn, William Hyman, (unknown), Donald Richards, Svetislava J. Vukelja, (unknown), Robert L. Ruxer, Kristi A. Boehm, Lina Asmar	11
7	Phase I Trial of Topotecan in Combination with Gemcitabine in Refractory Solid Tumor Patients 2004 ·Cancer Investigation ·John Nemunaitis, Casey Cunningham, (unknown), Robert L. Ruxer, Ned Adams, (unknown), Andrew Scott Paulson, (unknown)	3
8	Result of two randomized trials comparing nolatrexed (Thymitaq™) versus methotrexate in patients with recurrent head and neck cancer 2001 ·Annals of Oncology ·Xavier Pivot, Scott Wadler, C. Kelly, Robert L. Ruxer, J. Tortochaux, Jordan C. Stern, D Belpomme, Yves Humblet, C. Domenge, Neil J. Clendeninn, A. E. Johnston, C A Penning, M. Schneider	24
9	Double ?-lactam regimen compared to an aminoglycoside/?-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients 1993 ·Supportive Care in Cancer ·(unknown), Kathryn A. Newman, (unknown), Rebecca S. Finley, Robert L. Ruxer, Mark Moody, (unknown)	9
10	A phase II trial of continuous infusion vinblastine in patients with gastric carcinoma 1990 ·European Journal of Cancer and Clinical Oncology ·Daniel D. Von Hoff, (unknown), Cary A. Presant, Robert L. Ruxer, John S. Macdonald, John J. Costanzi, Ronald L. Stephens, (unknown)	3
11	Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma. 1986 ·Journal of Clinical Oncology ·Richard Leff, (unknown), David B. Johnson, (unknown), Mary B. Daly, W. Andy Knight, Robert L. Ruxer, Gerald L. Messerschmidt	32
12	Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients 1985 ·Antimicrobial Agents and Chemotherapy ·George L. Drusano, (unknown), Alan Forrest, Robert L. Ruxer, Harold C. Standiford, James Leslie, Janet R. Wade, Stephen C. Schimpff	13
13	Mesothelioma following Wilms' tumor in childhood 1984 ·Cancer ·Karen H. Antman, Robert L. Ruxer, Joseph Aisner, Gordon F. Vawter	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact